Updates · 20 Sep 2026
What this programme aims to establish
A plain account of what NWPharmaTech’s CHR-P workstream is trying to learn — and what it is not claiming today.
The candidate
Company materials describe NWPT-SM32300 as a 300 mg CBD micellar-emulsion softgel under investigation. Earlier internal names may appear in older documents; naming is being reconciled before detailed product claims. This is an investigational description — not an approved CHR-P medicine.
First catalytic scientific step
The working focus for a realistic first step is a rigorous evaluation of symptom and functioning outcomes that can be measured in a feasible trial window. That is the preferred catalytic use of early programme resources.
What is not established
- CHR-P efficacy for NWPT-SM32300 — not established
- Prevention of psychosis — mission question, not a demonstrated result
- Numerical bioavailability or safety claims vs Epidyolex — withheld until a signed clinical study report is on file
- Historical ~328-participant multi-site plans — planning precedent only, not a locked protocol
Sponsor governance
NWPharmaTech remains the pharmaceutical sponsor for clinical development, safety, CMC and regulatory strategy. Investigators, ethics committees and regulators keep their independent roles. Community or financing participants do not vote on protocol, dose, endpoints, safety or submissions.
Financing note (planning only)
Approximately $10 million is a working fundraising target for planning. It is not committed capital, a bottoms-up validated trial budget, or a priced offer. This public site does not accept investments.
Honest limitations
Field CBD studies (including adjunctive work in schizophrenia with other products) are hypothesis-generating only. They are not NWPT-SM32300 data and not CHR-P prevention evidence for this programme. See the evidence library for labelled sources.